142 related articles for article (PubMed ID: 28164348)
1. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.
Jairath V; Zou G; Parker CE; MacDonald JK; Mosli MH; AlAmeel T; Al Beshir M; AlMadi M; Al-Taweel T; Atkinson NS; Biswas S; Chapman TP; Dulai PS; Glaire MA; Hoekman D; Kherad O; Koutsoumpas A; Minas E; Restellini S; Samaan MA; Khanna R; Levesque BG; D'Haens G; Sandborn WJ; Feagan BG
Aliment Pharmacol Ther; 2017 Apr; 45(8):1021-1042. PubMed ID: 28164348
[TBL] [Abstract][Full Text] [Related]
2. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
Jairath V; Zou GY; Parker CE; MacDonald JK; AlAmeel T; Al Beshir M; Almadi MA; Al-Taweel T; Atkinson NS; Biswas S; Chapman T; Dulai PS; Glaire MA; Hoekman DR; Koutsoumpas A; Minas E; Mosli MH; Samaan M; Khanna R; Travis S; D'Haens G; Sandborn WJ; Feagan BG
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011572. PubMed ID: 28886205
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials.
Almradi A; Sedano R; Hogan M; Zou GY; MacDonald JK; Parker CE; Hanzel J; Crowley E; Singh S; D'Haens G; Sandborn WJ; Feagan BG; Ma C; Jairath V
J Crohns Colitis; 2022 Jun; 16(5):717-736. PubMed ID: 34758084
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
Jairath V; Zou G; Parker CE; Macdonald JK; Mosli MH; Khanna R; Shackelton LM; Vandervoort MK; AlAmeel T; Al Beshir M; AlMadi M; Al-Taweel T; Atkinson NS; Biswas S; Chapman TP; Dulai PS; Glaire MA; Hoekman D; Koutsoumpas A; Minas E; Samaan MA; Travis S; D'Haens G; Levesque BG; Sandborn WJ; Feagan BG
J Crohns Colitis; 2016 May; 10(5):607-18. PubMed ID: 26746169
[TBL] [Abstract][Full Text] [Related]
5. Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn's Disease: A Systematic Review and Meta-Analysis.
Sharma T; Ma C; Sedano R; Hanzel J; McDonald C; Hogan M; Kochhar GS; Narula N; Peyrin-Biroulet L; Danese S; MacDonald JK; Jairath V
J Crohns Colitis; 2023 Apr; 17(4):644-658. PubMed ID: 36271904
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
Sedano R; Hogan M; Nguyen TM; Chang J; Zou GY; Macdonald JK; Vande Casteele N; Hanzel J; Crowley E; Battat R; Dulai PS; Singh S; D'Haens G; Sandborn W; Feagan BG; Ma C; Jairath V
J Crohns Colitis; 2022 Feb; 16(2):224-243. PubMed ID: 34309658
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine for induction of remission in Crohn's disease.
McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease.
Su C; Lichtenstein GR; Krok K; Brensinger CM; Lewis JD
Gastroenterology; 2004 May; 126(5):1257-69. PubMed ID: 15131785
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysis.
Vuyyuru SK; Nguyen TM; Hogan M; Raine T; Noor NM; Narula N; Verstockt B; Feagan BG; Singh S; Ma C; Jairath V
Inflamm Bowel Dis; 2024 Apr; 30(4):651-659. PubMed ID: 37002875
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies.
Macaluso FS; Maida M; Ventimiglia M; Cottone M; Orlando A
Expert Opin Biol Ther; 2020 Feb; 20(2):193-203. PubMed ID: 31859538
[No Abstract] [Full Text] [Related]
15. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate for maintenance of remission in Crohn's disease.
Patel V; Macdonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2009 Oct; (4):CD006884. PubMed ID: 19821390
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
Ma C; Guizzetti L; Panaccione R; Fedorak RN; Pai RK; Parker CE; Nguyen TM; Khanna R; Vande Casteele N; D'Haens G; Sandborn WJ; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2018 Jun; 47(12):1578-1596. PubMed ID: 29696670
[TBL] [Abstract][Full Text] [Related]
18. Placebo Rates in Randomized Controlled Trials of Proctitis Therapy: A Systematic Review and Meta-Analysis Placebo Response in Proctitis.
De Silva TA; Alphonsus L; Ma C; Hogan M; Sedano R; Narula N; Danese S; Peyrin-Biroulet L; MacDonald JK; Singh S; Jairath V
J Crohns Colitis; 2023 Jan; 17(1):123-136. PubMed ID: 35930405
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate for induction of remission in refractory Crohn's disease.
Alfadhli AA; McDonald JW; Feagan BG
Cochrane Database Syst Rev; 2003; (1):CD003459. PubMed ID: 12535475
[TBL] [Abstract][Full Text] [Related]
20. Impact of Baseline Disease Activity and Trial Duration on Efficacy of Biologics in Active Crohn's Disease: Meta-analysis.
Barberio B; Gracie DJ; Black CJ; Ford AC
Inflamm Bowel Dis; 2023 Oct; 29(10):1594-1601. PubMed ID: 36637168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
